Peak Bio, Inc.

Peak Bio, Inc., trading under the ticker IGNY, is the post-combination entity resulting from a de-SPAC merger between Ignyte Acquisition Corp and Peak Bio, a clinical-stage biopharmaceutical company focused on oncology, including antibody-drug conjugate therapeutics. Ignyte Acquisition Corp completed its IPO in 2021, targeting the healthcare and life sciences sector. The business combination closed in 2022, and the company filed a 10-Q with the SEC on November 21, 2022, under accession number 0001193125-22-290073, reflecting its status as a newly public reporting entity in the biopharmaceutical space. Sign up for full data, filings, and deal history on SpacDesk.